The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer

European Journal of Medical Research

Zhenli Gao¹  Diandong Yang¹  Qingzuo Liu¹  Chunhua Lin¹  Changping Men¹  Ke Wang¹  Fan Feng¹  Shengqiang Yu¹ 

[1] Department of Urology, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University, NO.20 East Yuhuangding Road, 264000 Yantai, China

关键词: Cell apoptosis;    Monoclonal antibody;    Prostate stem cell antigen;    Prostate cancer;    Radioimmunotherapy;   

Others  :  817721
DOI  :  10.1186/2047-783X-18-56

 received in 2013-09-10, accepted in 2013-11-25,  发布年份 2013

【 摘 要 】

Background

Prostate stem cell antigen (PSCA) is upregulated in prostate cancer tissues. Here we aimed to study the therapeutic efficacy of a monoclonal antibody of PSCA-labeled I¹³¹ (I¹³¹-PSCA-mAb) in orthotopic mouse models of prostate cancer.

Methods

The proliferation, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I¹³¹-PSCA-mAb were measured by methyl thiazolyl tetrazolium assay, flow cytometry and transwell culture, respectively. The human prostate cancer models were established by orthotopic implantation of PC-3 and LNCaP cells in nude mice. I¹³¹-PSCA-mAb distribution and tumor cell apoptosis in the tumor-bearing nude mice were measured.

Results

The inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I¹³¹-PSCA-mAb reached a maximum of 84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I¹³¹-IgG or PSCA-mAb. The invaded number of PC-3 and LNCaP cells treated with I¹³¹-PSCA-mAbe was significantly reduced (P < 0.01) compared with the control group. The ratios of I¹³¹-PSCA-mAb in tumor to intramuscular I¹³¹-PSCA-mAb (T/NT) in tumor-bearing nude mice were increased with time and reached the highest level after 8 h. T/NT stayed above 3.0 after 12 h, and the tumor could still be developed after 24 h. The number of apoptotic cells in tumor tissue of nude mice treated with I¹³¹-PSCA-mAb was larger than that in the control group.

Conclusion

I¹³¹-PSCA-mAb has the potential to become a new targeted therapy drug for the treatment of prostate cancer.

【 授权许可】

   
2013 Yu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
• [2]La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F: Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 2010, 21:1323-1360.
• [3]Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al.: Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
• [4]Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A: Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol 2013, 7:1-12.
• [5]Huggins CHC: Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297.
• [6]Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002, 167:948-951. discussion 952
• [7]Hamberg P, Verhagen PC, De Wit R: When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008, 44:1193-1197.
• [8]Sternberg CN: Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 2008, 19(Suppl 7):vii91-vii95.
• [9]Gasent Blesa JM, Godoy MP, Esparcia MF, Molla SB, Magan BM, Sempere Ortells JM, Sanchez JL: PSA response to lenalidomide therapy in a pre-treated patient with metastatic prostate cancer refractory to hormones and chemotherapy: a case report. Case Rep Oncol 2012, 5:181-186.
• [10]Moul JW: Variables in predicting survival based on treating “PSA-only” relapse. Urol Oncol 2003, 21:292-304.
• [11]Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21:1232-1237.
• [12]Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al.: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998, 95:1735-1740.
• [13]Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19:1288-1296.
• [14]Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE: Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004, 171:1117-1121.
• [15]Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE: Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005, 11:2591-2596.
• [16]Saeki N, Gu J, Yoshida T, Wu X: Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010, 16:3533-3538.
• [17]Ahmad S, Casey G, Sweeney P, Tangney M, O’Sullivan GC: Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009, 17:1101-1108.
• [18]Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A: Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001, 98:2658-2663.
• [19]Fasquel JB, Agnus V, Moreau J, Soler L, Marescaux J: An interactive medical image segmentation system based on the optimal management of regions of interest using topological medical knowledge. Comput Meth Programs Biomed 2006, 82:216-230.
• [20]Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003, 30:667-676.
• [21]Raff AB, Gray A, Kast WM: Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 2009, 277:126-132.
• [22]Sharkey RM, Goldenberg DM: Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006, 56:226-243.
• [23]Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M: Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers 2012, 4:193-217.
• [24]Zalutsky MR, Pozzi OR: Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004, 48:289-296.
• [25]Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, et al.: A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003, 9:5842-5852.
• [26]Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, Casadevall A: Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A 2004, 101:14865-14870.
• [27]Chamarthy MR, Williams SC, Moadel RM: Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ’magic bullets’ to ‘radioactive magic bullets’. Yale J Biol Med 2011, 84:391-407.